![Pharmaceuticals | Free Full-Text | Antiproliferative Properties of Type I and Type II Interferon | HTML Pharmaceuticals | Free Full-Text | Antiproliferative Properties of Type I and Type II Interferon | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-03-00994/article_deploy/html/images/pharmaceuticals-03-00994-g001.png)
Pharmaceuticals | Free Full-Text | Antiproliferative Properties of Type I and Type II Interferon | HTML
![New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies - Journal of Hepatology New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies - Journal of Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/acc2aa60-b856-4883-a6f8-4b2d3d5f9b5a/gr1_lrg.jpg)
New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies - Journal of Hepatology
![Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus | Immunotherapy Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt-2016-0090/asset/images/medium/figure1.gif)
Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus | Immunotherapy
![References in Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial - The Lancet References in Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2000977426/2003577226/gr1.gif)
References in Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial - The Lancet
![Type I interferons in pancreatic cancer and development of new therapeutic approaches - ScienceDirect Type I interferons in pancreatic cancer and development of new therapeutic approaches - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1040842820303401-gr1.jpg)
Type I interferons in pancreatic cancer and development of new therapeutic approaches - ScienceDirect
![Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C | Nature Reviews Gastroenterology & Hepatology Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrgastro.2010.101/MediaObjects/41575_2010_Article_BFnrgastro2010101_Fig1_HTML.jpg)
Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C | Nature Reviews Gastroenterology & Hepatology
![Interferons α and β in cancer: therapeutic opportunities from new insights | Nature Reviews Drug Discovery Interferons α and β in cancer: therapeutic opportunities from new insights | Nature Reviews Drug Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41573-018-0011-2/MediaObjects/41573_2018_11_Fig2_HTML.png)
Interferons α and β in cancer: therapeutic opportunities from new insights | Nature Reviews Drug Discovery
![Pharmaceuticals | Free Full-Text | Antiproliferative Properties of Type I and Type II Interferon | HTML Pharmaceuticals | Free Full-Text | Antiproliferative Properties of Type I and Type II Interferon | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-03-00994/article_deploy/html/images/pharmaceuticals-03-00994-g002.png)